Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.
about
Applications of CYP450 testing in the clinical settingThe pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19Application of routine electronic health record databases for pharmacogenetic researchPoint-of-care platelet reactivity determination with VerifyNow-P2Y12 following administration of clopidogrel or prasugrel: data from a real-world, clinical care inpatient setting.Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction.Association between genetic polymorphisms of cytochrome P450 2C19 and the risk of cerebral ischemic stroke in Chinese.Impact of CYP2C19 Variants on Clinical Efficacy of Clopidogrel and 1-Year Clinical Outcomes in Coronary Heart Patients Undergoing Percutaneous Coronary Intervention.Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.Regulatory polymorphisms in CYP2C19 affecting hepatic expressionImpact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of ClopidogrelPharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.Clinical impact of genetically determined platelet reactivity.Ticagrelor: positive, negative and misunderstood properties as a new antiplatelet agent.Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics.Pharmacogenomics of anti-platelet and anti-coagulation therapy.Assessing post-treatment platelet reactivity: a focus on patient selection and setting.Cardiovascular pharmacogenomics: expectations and practical benefits.Pharmacogenomics of oral antiplatelet drugs.A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users.Comparison of new adenosine diphosphate receptor antagonists with clopidogrel in patients with coronary artery disease: a meta-analysis.Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome.A Knowledge-based System for Intelligent Support in Pharmacogenomics Evidence Assessment: Ontology-driven Evidence Representation and Retrieval.Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention.East Asian perspective on the interaction between proton pump inhibitors and clopidogrel.Comparison of aspirin and Naoxintong Capsule () with adjusted-dose warfarin in elderly patients with high-risk of non-valvular atrial fibrillation and genetic variants of vitamin K epoxide reductase.Amlodipine--not a significant contributor to clopidogrel non-response?Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite.Analysis of CYP2C19 Genetic Polymorphism in a Large Ethnic Hakka Population in Southern China.Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis.Integrative medicine on optimizing clopidogrel and aspirin therapy.Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis.A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism.
P2860
Q24621760-BAA53030-B462-4340-AF9C-DAF5D2E8B212Q26801867-EAB1380D-2A8C-4C8E-8761-05F978B9E9C1Q26864747-0A27B5DA-5590-49E1-8506-6F16BBE32C13Q30877943-D08F9C28-A8ED-4349-996B-81434911F7E8Q33923341-F74A8ADE-19D6-437D-A092-5FC8467B45A6Q34010627-197F0D7A-84B2-4B72-9BA1-6516B125A72EQ36216896-899EEF3F-DA16-48F0-90F3-B9FB143DD3BDQ36391044-AD58878D-79CB-46CE-B7C5-A6C48C8DCE5FQ37127419-748C1EBA-CF33-445F-8E2C-3EC9E7A0625DQ37639546-E4ABBB8E-DF48-4178-8A68-98338789F631Q37724614-91737B31-A15D-44B8-9A24-CE51AD712670Q38059616-34513A9B-D5C4-4150-A8CA-0223159431EFQ38099380-761C0995-7201-43BE-BCF3-BF655CF686ECQ38106616-DD8D39F6-7E1A-4B2E-8687-4ED6E25DED31Q38116753-49A79E93-9FFE-419A-BAC0-C2F1F39B7570Q38132923-7F485F7F-C5B1-4834-98F9-D4E0D2B6EE7CQ38169969-8A2E3562-9A4A-4E9E-8C4E-0010EB27DC33Q38195628-0D76A3EF-A26E-4CF3-ADE6-849B2326B5FAQ38221608-81BB4782-5304-4633-AF70-06C4CE5E2723Q38265442-C8652401-0D35-4CCF-AD4F-0188DDADF48BQ38380508-E765C52F-8D6F-4774-A456-897BC96B6FEFQ38429749-5FB701B5-FE72-4DB9-8E4C-F629223E52C0Q38682772-CC038C01-A774-45EE-94F9-BC8E8EA8A99CQ39055767-1FEDD032-AD94-4298-82C4-B3621BF17516Q39965332-30E102ED-181B-4454-A1EF-F3658BEDA8EDQ42703130-BABC2B69-EAE0-4EF8-A4DA-A99DF90D42C2Q47094164-659F5BB1-838C-4FD9-8B5D-DDDBB166C657Q47231767-3559DCA3-80CE-428A-8FC1-0FE63270379AQ47554139-77F4780B-B049-4E83-90AF-AC89BD28664FQ47652515-A6B1BDA5-0F5D-4585-8E1D-5AEF08F939FCQ50041672-6771A07F-F493-4034-8249-A5EE0119953DQ51235778-A8BEDD95-5C81-4D96-B433-257D42D152B2Q54183735-6ED2AD68-6C88-4B72-AE21-54C465A7B85D
P2860
Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Meta-analysis of cytochrome P4 ...... oups treated with clopidogrel.
@en
Meta-analysis of cytochrome P4 ...... oups treated with clopidogrel.
@nl
type
label
Meta-analysis of cytochrome P4 ...... oups treated with clopidogrel.
@en
Meta-analysis of cytochrome P4 ...... oups treated with clopidogrel.
@nl
prefLabel
Meta-analysis of cytochrome P4 ...... oups treated with clopidogrel.
@en
Meta-analysis of cytochrome P4 ...... oups treated with clopidogrel.
@nl
P2093
P1476
Meta-analysis of cytochrome P4 ...... oups treated with clopidogrel.
@en
P2093
Bo-Hyun Kim
Dae-Kyeong Kim
Dong-Soo Kim
Doo-Il Kim
Han-Young Jin
Hyung-Gon Je
Jeong-Sook Seo
Kyoung-Im Cho
Sang-Hoon Seol
Seung-Whan Lee
P304
P356
10.1016/J.AMJCARD.2012.04.020
P407
P50
P577
2012-05-15T00:00:00Z